Borja Gallego

Mr. Borja Gallego

Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Asturias, Spain
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
DMDzohara Murillo
Dzohara Murillo
CHCarmen Huergo
Carmen Huergo
BGBorja Gallego
Borja Gallego
RRRene Rodriguez
Rene Rodriguez
JTJuan Tornín
Juan Tornín
Drug resistance is a major problem in cancer treatment, as it limits the effectiveness of pharmacological agents and can lead to disease progression. Cold atmospheric plasma (CAP) is a technology that uses ionized gas (plasma) to generate reactive oxygen and nitrogen species (RONS) that can kill cancer cells. CAP is a novel approach for overcoming drug resistance in cancer. In recent years, there has been a growing interest in using CAP to enhance the effectiveness of chemotherapy drugs. In this review, we discuss the mechanisms behind this phenomenon and explore its potential applications in cancer treatment. Going through the existing literature on CAP and drug resistance in cancer, we highlight the challenges and opportunities for further research in this field. Our review suggests that CAP could be a promising option for overcoming drug resistance in cancer and warrants further investigation.

Verified
Journal Article
Open access
PDF file
STSofía Tirados
Sofía Tirados
BGBorja Gallego
Borja Gallego
DMDzohara Murillo
Dzohara Murillo
ARAida Rodríguez
Aida Rodríguez
RRRene Rodriguez
Rene Rodriguez
Bone sarcomas are commonly characterized by a high degree of intra-tumor heterogeneity, which in part is due to the presence of subpopulations of tumor cells presenting stem cell properties. Similar to normal stem cells, these cancer stem cells (CSCs) display a drug resistant phenotype and therefore are responsible for relapses and tumor dissemination. Drug resistance in bone sarcomas could be enhanced/modulated during tumor evolution though the acquisition of (epi)-genetic alterations and the adaptation to changing microenvironments, including drug treatments. Here we summarize findings supporting the involvement of pro-stemness signaling in the development of drug resistance in bone sarcomas. This include the activation of well-known pro-stemness pathways (Wnt/β-Cat, NOTCH or JAT/STAT pathways), changes in the metabolic and autophagic activities, the alteration of epigenetic pathways, the upregulation of specific non-coding RNAs and the crosstalk with different microenvironmental factors. This altered signaling is expected to be translated to the clinic in the form of biomarkers of response and new therapies able to overcome drug resistance.

2 March 2020 in Microchimica Acta
Verified
Journal Article
Closed access
PDF file
ASAdrián Sánchez-Visedo
Adrián Sánchez-Visedo
BGBorja Gallego
Borja Gallego
LRLuis J Royo
Luis J Royo
University of OviedoUniversity of Oviedo
University of Oviedo
MLMarta Valledor Llopis
Marta Valledor Llopis
José Manuel Costa FernándezJosé Manuel Costa Fernández
José Manuel Costa Fernández

Verified
Journal Article
Open access
PDF file
BGBorja Gallego
Borja Gallego
DMDzohara Murillo
Dzohara Murillo
VVVerónica Rey Vázquez
Verónica Rey Vázquez
CHCarmen Huergo
Carmen Huergo
ÓEÓscar Estupiñán
Óscar Estupiñán
RRRene Rodriguez
Rene Rodriguez
Bone sarcomas have not shown a significant improvement in survival for decades, due, in part, to the development of resistance to current systemic treatments, such as doxorubicin. To better understand those mechanisms mediating drug-resistance we generated three osteosarcoma and one chondrosarcoma cell lines with a stable doxorubicin-resistant phenotype, both in vitro and in vivo. These resistant strains include a pioneer model generated from a patient-derived chondrosarcoma line. The resistant phenotype was characterized by a weaker induction of apoptosis and DNA damage after doxorubicin treatment and a lower migratory capability. In addition, all resistant lines expressed higher levels of ABC pumps; meanwhile, no clear trends were found in the expression of anti-apoptotic and stem cell-related factors. Remarkably, upon the induction of resistance, the proliferation potential was reduced in osteosarcoma lines but enhanced in the chondrosarcoma model. The exposure of resistant lines to other anti-tumor drugs revealed an increased response to cisplatin and/or methotrexate in some models. Finally, the ability to retain the resistant phenotype in vivo was confirmed in an osteosarcoma model. Altogether, this work evidenced the co-existence of common and case-dependent phenotypic traits and mechanisms associated with the development of resistance to doxorubicin in bone sarcomas.

17 July 2023 in Microchimica Acta
Verified
Journal Article
Open access
PDF file
ASAdrián Sánchez-Visedo
Adrián Sánchez-Visedo
BGBorja Gallego
Borja Gallego
LRLuis J Royo
Luis J Royo
University of OviedoUniversity of Oviedo
University of Oviedo
MLMarta Valledor Llopis
Marta Valledor Llopis
José Manuel Costa FernándezJosé Manuel Costa Fernández
José Manuel Costa Fernández
MicroRNAs (miRNAs) represent a class of small noncoding RNAs that are considered a novel emerging class of disease biomarkers in a variety of afflictions. Sensitive detection of miRNA is typically achieved using hybridization-based methods coupled with genetic amplification techniques. Although their sensitivity has improved, amplification techniques often present erroneous results due to their complexity. In addition, the use of these techniques is usually linked to the application of protein enzymes, the activity of which is dependent on the temperature and pH of the medium. To address these drawbacks, an alternative genetic enzyme for the highly sensitive detection of miRNAs is proposed in this work. Multicomponent nucleic acid enzymes (MNAzymes), coupled with the use of DNA-functionalized gold nanoparticles (AuNPs), were used in this study to develop an isothermal signal amplification strategy for visual genetic detection. miR146a, a biomarker of bovine mastitis present in milk, was selected as a model analyte. The developed methodology is easily carried out in 80 min at 50 °C, generating a low visual limit of detection of 250 pM based on the observation of a color change. The methodology was successfully applied to the detection of miR146a in raw cow milk samples. Graphical Abstract